X4 Pharmaceuticals Inc
(FRA:48Q)
€
0.874
-0.006 (-0.68%)
Market Cap: 158.44 Mil
Enterprise Value: 137.33 Mil
PE Ratio: 0
PB Ratio: 168.33
GF Score: 33/100 - Q1 2024 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024€1.1 (+3.59%)Earnings
- Q4 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 21, 2024€0.915 (+4.57%)Earnings
- Q3 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023€0.68 (-9.33%)Earnings
- X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- X4 Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 10, 2023€1.03 (-31.79%)Earnings
- X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call TranscriptMay 16, 2023
- Q1 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023€1.29Earnings
- Q4 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 21, 2023€0.835 (+4.37%)Earnings
- X4 Pharmaceuticals Inc To Discuss Key Top-Line 4WHIM Trial Results TranscriptNov 29, 2022
- X4 Pharmaceuticals Inc at Stifel Healthcare Conference TranscriptNov 15, 2022
- Q3 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022€1.95 (+3.17%)Earnings
- X4 Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 11, 2022
- Q2 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2022€1.28 (+13.27%)Earnings
- Q1 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022€0.985 (-7.94%)Earnings
- X4 Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 17, 2022€1.77 (-1.12%)Earnings
- X4 Pharmaceuticals Inc at B Riley Oncology Conference (Virtual) TranscriptJan 28, 2022
- Q3 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 04, 2021€4.92 (+5.58%)Earnings
- X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2021€5.05 (+6.09%)Earnings
- Q1 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2021€6.55 (-5.07%)Earnings
- Q4 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 04, 2021€8 (+0.63%)Earnings
- X4 Pharmaceuticals Inc Dr. Ragan Discusses X4's Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases TranscriptDec 23, 2020
- Q3 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020€5.35 (+1.90%)Earnings
- Q2 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptJul 30, 2020€6.7 (-2.90%)Earnings
- X4 Pharmaceuticals Inc Post-EHA Corporate Update TranscriptJun 12, 2020
- Q1 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020€8.1 (-2.41%)Earnings
- X4 Pharmaceuticals Inc Virtual Analyst Day - A Deep Dive into WHIM Syndrome TranscriptApr 07, 2020
- Q4 2019 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 12, 2020€7.46 (-5.09%)Earnings
- Q3 2019 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019Earnings
X4 Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022 / 02:30PM GMT
Release Date Price:
€1.32
(-0.75%)
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good morning. My name is Arlinda Lee, and I'm a senior biotech analyst at Canaccord Genuity. It's my pleasure to introduce Dr. Paula Ragan, the CEO of X4 Pharmaceuticals. Paula, thanks for joining us today.
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Thanks so much for having me, Arlinda. Nice to see you.
Questions & Answers
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good to see you, too. So for investors who are new to the X4 story, can you provide an overview of what X4 does? The diseases you intend to treat, and market opportunities in terms of patient size.
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Yeah. So we are a company focused on diseases that are anchored in dysregulation of the immune system. And I'm sure people can appreciate how broad that might encompass, but we're focused on two key therapeutic areas. There are patients that are born with any deficiencies in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)